NCT07021157 - A Study to Evaluate the Safety, Tolerability and PK of SK-08 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 9, 2025

Primary Completion Date

August 7, 2025

Study Completion Date

August 7, 2025

Conditions

Chronic Kidney Disease(CKD)

Interventions

DRUG

SK-08

Dose groups of 5 mg, 7.5mg,12.5 mg, 30 mg, 45 mg, and 60 mg were given SK-08 once.

DRUG

Placebo

Dose groups of 5 mg, 7.5mg,12.5 mg, 30 mg, 45 mg, and 60 mg were given placebo once.

Trial Locations (1)

RECRUITING

The First Affiliated Hospital，Zhejiang University, Hangzhou